Search
for
Sort by
Research 391–420 of 519
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- The Sebaceous Gland - Friend or Foe?
- <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Excellent response to tofacitinib treatment in a patient with alopecia universalis
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
- Alopecia Areata: Current Review
- A novel hairless highly immunodeficient mice model optimized for in vivo imaging
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHES